Welcome to a new era of psychedelics.
@psilera
@psilera
Location: United States
Total raised: $11.3M
Investors 3
| Date | Name | Website |
| - | JLS Fund | jls.fund |
| - | Iter Inves... | iterinvest... |
| - | What If Ve... | whatif.vc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.06.2026 | Seed | $8.8M | - |
| 01.07.2021 | Seed | $2.5M | - |
Mentions in press and media 18
| Date | Title | Description |
| 01.06.2026 | Psilera Secures $8.8M, Propels Novel Neuroplastogen to Human Trials | Psilera secures $8.8M seed funding, propelling its lead neuroplastogen, PSIL-006, towards 2027 human trials. PSIL-006 offers psychedelic-inspired therapeutic benefits with minimized hallucinogenic and cardiovascular risks. This pivotal capi... |
| 01.06.2026 | Psilera Secures $8.8M Seed Extension | TAMPA, FL, Psilera has announced the successful closing of an oversubscribed $8.8 million Series Seed extension funding round. >> Click here for more funding data on Psilera >> To export Psilera funding data to PDF and Excel, c... |
| 28.05.2026 | Psilera Raises $8.8M in Seed Funding | Psilera, a Tampa, FL-based biopharmaceutical company providing new neuroplastogens and psychedelic therapies, raised $8.8M in Seed funding. Backers were not disclosed. The company intends to use the funds to advance its lead clinical asset,... |
| 28.05.2026 | Psilera: $8.8 Million Seed Round Closed To Advance Neuroplastogen PSIL-006 Into Clinical Trials | Psilera announced the closing of an oversubscribed $8.8 million Series Seed extension funding round led by a syndicate of institutional and strategic investors. The company said the capital will be used to advance its lead clinical asset, P... |
| 28.05.2026 | Triomics Raises $22M in Series B Funding | Triomics, a NYC-based oncology AI company helping cancer centers operationalize complex clinical information, raised $22M in Series B funding. The round was led by Battery Ventures, with participation from existing investors Nexus Venture P... |
| 27.03.2023 | Here are the 15 hottest startups in the psychedelics industry, according to top investors | From left: Sherry Rais, a cofounder and the CEO of Enthea; Mark Rus, the CEO of Delix Therapeutics; Jackie von Salm, a cofounder and the CSO of Psilera; Jimmy Qian, a cofounder and the president of Osmind. Sherry Rais/Enthea; Mark Rus/Delix... |
| 12.12.2021 | Psilera creates a new era of mindful medicine | What is Psilera? Psilera is a biotechnology company solving challenges with classic psychedelic compounds by optimizing dose via formulation and reducing off target effects (cardiotoxicity, hallucinations, etc) to increase scalability and ... |
| 07.12.2021 | Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies | This biological data is key to our vision of reducing side effects such as hallucinations while further optimizing classical psychedelics into next-generation drugs TAMPA, Fla. (PRWEB) December 07, 2021 Psilera Inc. (“Psilera”), a Florida-b... |
| 26.08.2021 | Psilera Collaborates with the National Institute on Drug Abuse (NIDA) to Research DMT and New Analogues to Combat Addiction | This collaboration serves as validation to our approach and scientific reputation within the psychedelic and biotech industry more broadly. We look forward to building out the next generation of mental health and addiction medications in co... |
| 12.08.2021 | Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at Reducing Alcohol Consumption | We consider this yet another important step towards our understanding of psychedelic and psychedelic-inspired compounds, and their potential as future medicines in the field of addiction TAMPA, Fla. (PRWEB) August 12, 2021 Psilera Inc. (“Ps... |
Show more